Keyword Company EPIC/TIDM SEDOL/ISIN News Price Announcements Fundamentals News Article RSS Renalytix AI PLC (RENX) Add to Alerts list Print Mail a friend Wednesday 01 April, 2020 Renalytix AI PLC RNS Number : 3212I Renalytix AI PLC 01 April 2020 Renalytix AI plc
Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that further to RNS Reach 2937H on 24 March 2020, Boston Healthcare Associates has presented data on KidneyIntelX™, the Company’s AI-enabled in
Presentation titled: Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression Oral presentation accepted for Late Breaking session of the National Kidney Foundation Spring Clinical Meeting Accompanying
Download full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces its unaudited interim results for the six months ended 31 December 2019, a period of considerable progress in advancing
Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it will release its interim results for the six months ended 31 December 2019, on Tuesday 3 March 2020. Investor briefing A briefing open to all investors will take
Download full announcement Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the Cowen 40th Annual Health Care Conference, which runs from the 1-4 March 2020, hosted at Boston Marriott Copley
Download full announcement Utah issues CLIA Certificate of Registration to allow patient testing New laboratory enables five-fold test volume increase to support 2020 commercial goals Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney
Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that that the national price for KidneyIntelX™ set by the Centers for Medicare and Medicaid Services ("CMS") became effective as of 1 January 2020.
Download full announcement US National pricing of $950 effective as of January 1 st , 2020 Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that that the Centers for Medicare and Medicaid Services (“CMS”) has released
